CV Sciences (CVSI) Total Non-Current Liabilities (2013 - 2026)
CV Sciences (CVSI) posted Total Non-Current Liabilities of $5.2 million for Q1 2026, down 4.91% sequentially from $5.5 million in Q4 2025, and down 10.99% YoY from $5.9 million in Q1 2025.
CV Sciences (CVSI) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
CV Sciences has reported Total Non-Current Liabilities for 11 years, with the latest figure at $5.2 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 10.99% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 10.99% YoY) and the FY2025 annual result came in at $5.5 million, down 10.4% from the prior year.
- Total Non-Current Liabilities slipped to $5.2 million in Q1 2026 per CVSI's latest filing, from $5.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $13.5 million in Q4 2022 and troughed at $5.2 million in Q1 2026.
- A 5-year average of $6.6 million and a median of $6.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities tumbled 54.18% in 2023, then dropped 0.97% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $13.5 million in 2022, then sank by 54.18% to $6.2 million in 2023, then dropped by 0.97% to $6.1 million in 2024, then slipped by 10.4% to $5.5 million in 2025, then declined by 4.91% to $5.2 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $5.2 million, $5.5 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | 4.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.95 Mn |
| Mar 31, 2026 | 5.22 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 5.87 Mn |
| Dec 31, 2024 | 6.13 Mn |
| Sep 30, 2024 | 6.16 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 6.19 Mn |
| Dec 31, 2022 | 13.51 Mn |
| Dec 31, 2020 | 19.41 Mn |
| Sep 30, 2020 | 18.96 Mn |
| Jun 30, 2020 | 23.71 Mn |
| Mar 31, 2020 | 21.94 Mn |
| Dec 31, 2019 | 23.13 Mn |
| Sep 30, 2019 | 23.00 Mn |
| Jun 30, 2019 | 17.37 Mn |
| Mar 31, 2019 | 17.08 Mn |